Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

July 8, 2019

Study Completion Date

July 8, 2019

Conditions
Alopecia Areata
Interventions
DRUG

CTP-543

Administered as tablets.

DRUG

CTP-543 matching placebo

Administered as tablets.

Trial Locations (13)

10029

Icahn School of Medicine at Mt. Sinai, New York

27104

Wake Forest University Health Sciences, Winston-Salem

33472

Siperstein Dermatology Group, Boynton Beach

44195

Cleveland Clinic, Cleveland

55432

Minnesota Clinical Study Center, Fridley

60611

Northwestern University, Chicago

77056

Suzanne Bruce & Associates, PA, Houston

92270

Contour Dermatology & Cosmetic Surgery Center, Rancho Mirage

92697

University of California, Irvine, Irvine

94064

Stanford University School of Medicine, Redwood City

94118

Kaiser Permanente Northern California, San Francisco

97210

Northwest Dermatology, Portland

06519

Yale School of Medicine, New Haven

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY